Omnyx, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center, announced this week it is launching its new digital pathology software, Dynamyx.

The software was developed to help pathologists diagnose cancer faster and with more accuracy; it will allow clinicians to view images and collaborate in real-time.

“As cancer care increases in volume and complexity, the essential need for technology and innovation mounts,” Mamar Gelaye, Omnyx CEO, said in a prepared statement. “We at Omnyx understand the burden on clinicians and the stakes for patients. Dynamyx represents our direct response to this growing need for healthcare providers. Dynamyx connects pathologists and other care providers, allowing them to efficiently and securely share their expertise and collaborate. Omnyx is proud to offer more value to the market.”

Back in January, the Digital Pathology Association said it suggests digital pathology manufacturers looking into marketing whole slide imaging devices proceed with submitting de novo applications to the FDA instead of premarket applications. This suggested such devices may soon be viewed as Class II devices and not Class III, which is the FDA’s highest risk classification.